DaVita Inc. 3rd Quarter 2026 Results

DaVita reported Q3 2026 revenue of $3.578 billion, up 4.6% year over year, and adjusted diluted EPS of $3.82; GAAP diluted EPS was $3.40 versus $2.04 a year earlier. The company raised the low end of its 2026 adjusted operating income outlook by $25 million to $2.175 billion and the low end of adjusted diluted EPS guidance by $0.20 to $14.30. Results included a $62 million impairment charge related to its China business, reducing DaVita-attributable net income by $27 million; quarterly free cash flow fell to $276 million from $604 million a year earlier. DaVita repurchased 0.6 million shares for $111 million during the quarter.

Analysis

DaVita’s guidance increase is a modest positive, but the underlying earnings quality is mixed. The key near-term issue is unit economics: U.S. revenue per treatment slipped while patient-care cost per treatment rose sequentially, squeezing contribution before overhead; with normalized non-acquired volume growth subdued, volume is not yet a reliable offset. The call should clarify whether supply costs are temporary or whether labor, benefits, and reimbursement mix are creating persistent margin pressure.

The less visible swing factor is integrated kidney care: sequential segment income fell sharply as risk-based membership and attributed spend expanded. That may reflect timing and benchmark estimation, not a deterioration in the core dialysis franchise, but it raises execution and earnings-volatility risk as the book grows. China impairment is non-cash and localized; avoid treating it as evidence of broad U.S. asset impairment.

Capital allocation deserves more scrutiny than the buyback headline. Trailing free cash flow has weakened while net debt and leverage edged higher, yet repurchases continued after quarter-end. Buybacks support per-share results, but sustained repurchases at the expense of deleveraging would increase sensitivity to higher borrowing costs and any reimbursement or labor shock. The raised adjusted outlook helps the 1–3 month setup; the 6–18 month question is whether cost per treatment stabilizes and cash conversion recovers. Consensus may over-credit the adjusted EPS outlook and underweight core cost spread and IKC volatility. No valuation or post-release price data are supplied, so avoid chasing the open.

Key Decisions for Investors

• Do not chase the initial reaction. After the earnings call, consider a measured long DVA only if management characterizes the treatment-cost increase as transitory and supports the raised outlook with credible Q4 operating assumptions; otherwise keep exposure at benchmark weight.
• Track revenue less patient-care cost per treatment, normalized non-acquired treatment growth, and IKC segment profitability over the next quarter. A persistent cost/reimbursement spread deterioration alongside flat volume would falsify the constructive earnings thesis.
• Treat the $1.0–$1.25 billion free-cash-flow outlook as a capital-allocation test: verify Q4 cash conversion and whether repurchases are funded without further leverage creep. If cash generation misses the implied path or leverage rises materially, reduce DVA exposure rather than assuming buybacks will support the stock.
• Watch for clarification of IKC benchmark adjustments and attribution timing on the call; until then, do not extrapolate the quarter’s segment volatility into a structural loss or credit the growing risk-based book as durable incremental profit.